Skip to main content
Premium Trial:

Request an Annual Quote

Sequitur, Procter and Gamble Pharmaceuticals to Collaborate on Target Validation Study

NEW YORK, Oct. 9 – Sequitur has entered into an agreement with Procter and Gamble Pharmaceuticals to provide the company access to its functional genomics technology, the companies announced Tuesday.

Sequitur, based in Natick, Mass., will perform biological screening and supply its proprietary antisense compounds and methods to Procter and Gamble for use in its target validation studies as part of a multi-year agreement, according to the companies. 

Financial details were not disclosed. 

“We are pleased to enter into this collaboration with Sequitur, which promises to accelerate the validation of our genomic targets across our therapeutic areas,” Gordon Hassing, vice president of R&D at Procter and Gamble Pharmaceuticals, said in a statement.

In September, Sequitur signed a multi-year agreement with Minneapolis-based Discovery Genomics to collaborate on screening antisense compounds and studying gene function in zebra fish.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.